+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients



Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients



Transplantation 87(3): 424-435



The aim of this prospective, multicenter, noncomparative, open-label trial was to evaluate the prophylactic use of caspofungin in adult liver transplant recipients at high risk of developing invasive fungal infections (IFI). Patients received caspofungin for at least 21 days. A successful treatment outcome was defined as the absence of breakthrough IFI during the first 100 days after the onset of caspofungin. According to study design, 71 patients were included. In the modified intention-to-treat analysis, successful treatment outcome was obtained in 88.7%. Two patients developed IFI: a Mucor and a Candida albicans surgical wound infections, respectively. Six more patients discontinued caspofungin because of drug-related altered liver function. No clinical side effects were related to caspofungin. Altered analytical data compatible with grade IV toxicity, irrespective of caspofungin attribution, were observed in 27.7% of patients at the end of caspofungin prophylaxis and in 15.4% of patients in safety visit (14 days after ending caspofungin administration) (P=0.13). Eight patients died, six during caspofungin administration and two during follow-up period, but none were attributed to IFI or caspofungin toxicity. These results show that caspofungin could be considered an efficacious and well-tolerated drug as antifungal prophylaxis in high-risk liver transplant recipients.

(PDF emailed within 0-6 h: $19.90)

Accession: 055232536

Download citation: RISBibTeXText

PMID: 19202450

DOI: 10.1097/TP.0b013e3181932e76


Related references

Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. Journal of Antimicrobial ChemoTherapy 52(5): 813-819, 2003

Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. American Journal of Transplantation 14(12): 2758-2764, 2015

Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis. Liver Transplantation 22(4): 427-435, 2015

Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation 96(6): 573-578, 2013

Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplantation Proceedings 37(9): 3965-3967, 2006

Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 315, 2002

Preemptive prophylaxis with lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring dialysis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 381, 2000

Risk factors for invasive fungal infections in liver transplant recipients. Chinese Medical Journal 125(2): 400-400, 2012

Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation 92(3): 346-350, 2011

Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 71(7): 910-913, 2001

Fungal infection prophylaxis in high-risk liver transplant recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 490, 1998

Risk factors for early invasive fungal infections in pediatric liver transplant recipients. Mycoses: -, 2018

Antifungal prophylaxis with liposomal amphotericin B and caspofungin in high-risk patients after liver transplantation: impact on fungal infections and immune system. Infectious Diseases 48(2): 161-166, 2016

Impact of targeted antifungal prophylaxis in heart transplant recipients at high risk for early invasive fungal infection. Transplantation 97(11): 1192-1197, 2014

Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transplantation 13(12): 1743-1750, 2007